Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Thoracic 6Gastrointestinal 5Genitourinary 4Lymphoid 3Tumor-Agnostic 2Gynecologic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Adrenocortical Carcinoma 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × antineoplaston AS 2-1 × Endocrine × Clear all
NCT00003453 2018-05-09

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Burzynski Research Institute

Phase 2 Terminated
6 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡